This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease

This study has suspended participant recruitment.
Information provided by (Responsible Party):
Exsar Corporation Identifier:
First received: October 27, 2011
Last updated: February 12, 2013
Last verified: February 2012
Ambroxol is expected to improve the signs and symptoms of patients with Type I Gaucher Disease.

Condition Intervention Phase
Type I Gaucher Disease Drug: Ambroxol Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Dose Escalation With 2 Dose Levels, Proof-of-Concept Clinical Trial of Ambroxol for the Treatment of Type I Gaucher Disease

Resource links provided by NLM:

Further study details as provided by Exsar Corporation:

Primary Outcome Measures:
  • Safety assessment based on potential changes in physical exam, vital signs, ECG, adverse event query, and clinical lab results, when compared to baseline values. [ Time Frame: Safety will be assessed at baseline and biweekly for 2 months. ]
    Safety will be based on physical exam, vital signs, ECG, adverse event query, and clinical pathology (includes chemistry, hematology and coagulation), asessed at baseline and approximately biweekly during the study.

Secondary Outcome Measures:
  • efficacy based on biomarker (glucocerebrosidase activities), lab results, as well as hepatic and splenic volumes from imaging scans. [ Time Frame: Biomarker, lab results (phenotype), as well as hepatic and spenic volumes will be assessed at baseline and after 2 months of treatment, and lab results (phenotypes) will also be assessed biweekly during the 2-month treatment period. ]
    Efficacy is based on biomarker (glucocerebrosidase activities), phenotypes according to specific lab results (acid phosphatase, angiotensin-converting enzyme, serum bilirubin, hemoglobin, platelet counts, peripheral blood leukocyte counts, serum iron, clotting time, etc.), as well as hepatic and splenic volumes.

Estimated Enrollment: 20
Study Start Date: December 2012
Estimated Study Completion Date: August 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ambroxol
Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
Drug: Ambroxol
Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
Other Name: Mucosolvon®

Detailed Description:

This is an Open-Label, Dose Escalation with 2 Dose Levels, Proof-of-Concept Clinical Trial of Ambroxol for the Treatment of Patients with Type I Gaucher Disease.

This study is a randomized clinical trial involving 20 evaluable patients affected with Type 1 Gaucher disease who are responsive to Ambroxol in vitro. There are 2 treatment groups, involving 2 dose levels of Ambroxol (187.5 and 225 mg/day), given once daily PO for 2 months in both groups. The 187.5-mg/day dose level will be tested first. If there are no significant adverse events, defined as >Grade 3 toxicity according to the latest version of the National Cancer Institute (NCI) Common Toxicity Criteria (CTC), the 225-mg/day dose level will be tested.


Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Biochemically and genetically confirmed diagnosis of Gaucher disease caused by β-glucocerebrosidase deficiency resulting from mutations in the GBA genes, which have been shown to respond to Ambroxol according to in vitro screening assay.
  • Must be 16 years of age or older at the time of study initiation.
  • With an intact, enlarged spleen.
  • A hemoglobin level of at least 10 g/L.
  • Able to understand and cooperate with the requirements of the study protocol.
  • Mentally competent, have ability to understand and willingness to sign the informed consent form.
  • Able to travel to a participating study site.
  • Women of child-bearing potential must use accepted contraceptive methods, and must have a negative serum or urine pregnancy test within one week prior to treatment initiation. An additional pregnancy test is to be performed, and results obtained, prior to administration of the first dose of Ambroxol.
  • Fertile men must practice effective contraceptive methods during the study period, unless documentation of infertility exists.
  • Body weight >40 kg (88 lbs).

Exclusion Criteria:

  • Receipt of any form of glucocerebrosidase <<4 weeks prior study initiation.
  • Total splenectomy.
  • Serious medical illness, significant cardiac disease, chronic bronchitis, emphysema, and cystic fibrosis, as well as disorders causing ventilation perfusion mismatch.
  • Substance abuse.
  • Any complex disease that may confound treatment assessment.
  • Pregnant women, or women of child-bearing potential not using reliable means of contraception.
  • Lactating females because of the potential for adverse reactions in nursing infants.
  • Fertile men unwilling to practice contraceptive methods during the study period.
  • Unwilling or unable to follow protocol requirements.
  • Known hypersensitivity reactions, intolerance or adverse reactions to Ambroxol or to the inactive ingredients.
  • Evidence of systemic infection, or serious infection within the past month.
  • Known to have HIV infection.
  • Known to have hepatitis B or hepatitis C.
  • Patients with a history of convulsive disorders.
  • Patients receiving any other investigational treatment for any indication within the past 4 weeks prior to initiation of Ambroxol treatment.
  • A history of cancer of any type.
  • Patients who have received immunotherapy of any type within the past 4 weeks prior to study initiation.
  • Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01463215

United States, New Jersey
ExSAR Corporation
Monmouth Junction, New Jersey, United States, 08852
Sponsors and Collaborators
Exsar Corporation
Study Chair: Robert Johnston Exsar Corporation
  More Information

Responsible Party: Exsar Corporation Identifier: NCT01463215     History of Changes
Other Study ID Numbers: CL-Ambroxol-002
Study First Received: October 27, 2011
Last Updated: February 12, 2013

Keywords provided by Exsar Corporation:
Type I Gaucher Disease

Additional relevant MeSH terms:
Gaucher Disease
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders
Respiratory System Agents processed this record on August 21, 2017